Susoctocog alfa

From Wikipedia, the free encyclopedia

Susoctocog alfa
Clinical data
Trade namesObizur
Other namesAntihemophilic factor (recombinant)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Drug classAntihemophilic factor
ATC code
Legal status
Legal status
  • UK: POM (Prescription only) [2]
  • US: ℞-only [3]
  • EU: Rx-only [4]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
UNII
KEGG

Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.[4][3][5]

Susoctocog alfa was approved for medical use in the United States in October 2014,[6][7] and for medical use in the European Union in November 2015.[4]

Factor VIII is one of the proteins needed for normal clotting of the blood.[4]

References[edit]

  1. ^ "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Retrieved 6 March 2020.
  2. ^ "Obizur 500 U powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 13 April 2017. Retrieved 3 September 2020.
  3. ^ a b "Obizur (antihemophilic factor- recombinant, porcine sequence kit". DailyMed. 2 January 2020. Retrieved 6 March 2020.
  4. ^ a b c d "Obizur EPAR". European Medicines Agency. 6 March 2020. Retrieved 6 March 2020.
  5. ^ Burness CB, Scott LJ (May 2016). "Susoctocog Alfa: A Review in Acquired Haemophilia A". Drugs. 76 (7): 815–21. doi:10.1007/s40265-016-0576-1. PMID 27098420.
  6. ^ "Obizur". U.S. Food and Drug Administration (FDA). 13 March 2018. Archived from the original on 23 April 2019. Retrieved 6 March 2020.
  7. ^ "Obizur". U.S. Food and Drug Administration (FDA). 27 September 2019. STN: BL 125512. Retrieved 6 March 2020.

External links[edit]